Advertisement
AMGN or GILD or MRK
Which Stock Would AI Choose? Amgen (AMGN) vs. Gilead Sciences (GILD) vs. Merck (MRK) Stock Comparison
Key Takeaways
- AMGN (Amgen) is balancing strong cardiometabolic and rare-disease growth against accelerating biosimilar erosion in its bone-health franchise.
- GILD (Gilead Sciences) is leveraging a durable HIV franchise and a fast-growing prevention (PrEP) business, with recent acquisitions compressing near-term earnings.
- MRK (Merck) has posted standout relative performance on pipeline momentum, even as roughly half its revenue still depends on the Keytruda oncology franchise ahead of its 2028 patent expiry.
- All three are large-cap biopharmaceutical names with mature dividend profiles, but they diverge sharply on growth drivers, valuation, and catalyst mix.
- Relative performance and market positioning have favored MRK and GILD over the trailing year, while AMGN trades near richer multiples relative to its consensus targets.
Introduction
This stock comparison examines three of the largest names in biopharmaceuticals: Amgen (AMGN), Gilead Sciences (GILD), and Merck & Co. (MRK). Although all three operate in the same broad sector, each faces a distinct set of catalysts and risks, from patent expiries to pipeline readouts and M&A (mergers and acquisitions). The comparison is most relevant to investors and traders weighing defensive dividend income against exposure to late-stage pipeline momentum and relative performance. Understanding how each company is positioned on growth, valuation, and near-term catalysts can help frame which profile best suits a given market view.
AMGN Overview and Recent Performance
Amgen is a diversified biotechnology leader spanning oncology, cardiometabolic disease, bone health, inflammation, and rare disease. In recent quarters, the company has leaned on a handful of growth drivers to offset pressure on legacy products. Repatha, Evenity, and Tezspire have grown in the high double digits, while rare-disease and biosimilar segments have also expanded. This momentum supported a revenue beat and a raised full-year outlook in recent results.
At the same time, the loss of exclusivity on bone-health drugs Prolia and XGEVA has driven meaningful sales declines, a trend management has characterized as consistent with expectations. The obesity program remains a focal point, with MariTide advancing through multiple late-stage studies even after the company discontinued a separate candidate. The stock has appreciated over the trailing twelve months, though it now trades above the average analyst price target, signaling that much of the favorable execution is already reflected in the share price.
GILD Overview and Recent Performance
Gilead Sciences is best known for its leadership in HIV treatment and prevention, anchored by Biktarvy and the growing pre-exposure prophylaxis (PrEP) franchise built around Yeztugo (lenacapavir). Recent quarters have shown solid revenue growth, driven by the HIV portfolio and contributions from oncology therapy Trodelvy and liver-disease treatments. The company has also raised its full-year product sales guidance.
The recent period has been defined by an active dealmaking push, with acquisitions including Arcellx, Tubulis, and Ouro Medicines. These transactions produced large in-process research and development (IPR&D) charges that swung reported earnings negative in the latest quarter, even as underlying product momentum stayed intact. Positive Phase 2 data for oral emvistegrast in ulcerative colitis has reinforced the inflammation pipeline narrative. Shares have outperformed the broader market over the past year, with analysts holding a broadly constructive consensus view and a meaningful dividend yield relative to the S&P 500.
MRK Overview and Recent Performance
Merck & Co. is a global pharmaceutical company whose results remain heavily concentrated in the Keytruda oncology franchise, which accounts for roughly half of total revenue. The market's attention is firmly on how the company manages the approach to Keytruda's loss of exclusivity (LOE), expected in 2028. In response, Merck has accelerated pipeline development and business development, including the acquisition of Terns Pharmaceuticals and its pipeline assets.
Recent clinical and regulatory wins have powered an exceptional run in the shares, which have climbed sharply over the trailing year and reached a 52-week high. Positive data for the personalized cancer therapy program with Moderna, the approval of oral PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor Lipfendra, and rapid growth from Winrevair have all reinforced investor confidence in a post-Keytruda growth strategy. However, the stock now trades at a premium valuation, and a legal setback over subcutaneous Keytruda in parts of Europe has added a new risk variable to an otherwise positive narrative.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page curates a selection of its AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each built with its own trading style, strategy, timeframe, and risk profile. Because not every bot suits every market environment, only those best aligned with current conditions earn a place in the curated Trending AI Robots section. The bots differ in performance statistics, drawdown characteristics, and the specific sets of tickers they monitor, giving users a range of approaches rather than a one-size-fits-all signal. Exploring the Trending AI Robots page can help traders identify automated strategies tailored to names like AMGN, GILD, and MRK.
Head-to-Head Comparison
The three companies diverge most clearly on business-model concentration and growth drivers. Gilead is the most franchise-dependent on a therapeutic area, but its HIV leadership and PrEP expansion provide comparatively stable, high-margin recurring revenue. Merck is even more concentrated at the product level, with Keytruda still the dominant contributor, yet it offers the deepest visible pipeline opportunity and the strongest recent momentum. Amgen sits between the two, with a more diversified portfolio that spreads risk across multiple therapeutic areas but lacks a single dominant growth engine.
On valuation, the trade-offs are pronounced. MRK trades at a substantial premium on forward earnings after its sharp run, reflecting high expectations for pipeline conversion. AMGN also carries an above-peer multiple and trades near or above consensus targets. GILD, by contrast, has historically screened cheaper relative to large-cap biopharma peers, partly due to past HIV franchise concerns that recent approvals have helped address. Risk profiles differ as well: AMGN faces biosimilar erosion, GILD faces integration and concentration risk, and MRK faces the largest single-product patent cliff of the group.
Tickeron AI Verdict
Based on observable trend consistency, catalyst breadth, and relative positioning, Tickeron's AI would most likely favor GILD on a balance of stability and upside. Its combination of a durable, growing core franchise, a constructive analyst consensus, a comparatively reasonable valuation, and fresh pipeline catalysts offers a steadier trend profile than the richer multiples attached to MRK or the biosimilar headwinds facing AMGN. That said, MRK retains the strongest momentum and the deepest long-term pipeline optionality, making it the higher-beta candidate. This is a probabilistic assessment based on current positioning rather than a definitive forecast, and rankings could shift as new trial data, approvals, and earnings updates arrive.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AMGN in upward trend: 10-day moving average broke above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMGN's RSI Indicator exited the oversold zone, 19 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 41 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 24, 2026. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in 27 of 47 cases over the following month. The odds of a continued upward trend are 57%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 189 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.276) is normal, around the industry mean (-3.196). P/E Ratio (27.025) is within average values for comparable stocks, (21.213). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.041) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
GILD's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for GILD turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 38 of 55 cases over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on GILD as a result. In 52 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
Following a +6.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 216 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 136 of 271 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 29 of 61 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 17 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.099) is normal, around the industry mean (-3.196). GILD's P/E Ratio (-58.839) is considerably lower than the industry average of (21.213). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.021) settles around the average of (0.041) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
MRK in upward trend: price may jump up because it broke its lower Bollinger Band on October 05, 2026
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 35 cases where MRK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 52 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on MRK as a result. In 51 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 20, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 28 of 51 cases over the following month. The odds of a continued upward trend are 55%.
MRK moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 192 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 31%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.818) is normal, around the industry mean (-3.196). MRK's P/E Ratio (118.952) is considerably higher than the industry average of (21.213). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.041) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
AMGN | GILD | MRK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 72 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 24 Undervalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 6 | 10 | 28 | |
SMR RATING 1..100 | 15 | 96 | 79 | |
PRICE GROWTH RATING 1..100 | 7 | 17 | 9 | |
P/E GROWTH RATING 1..100 | 28 | 100 | 1 | |
SEASONALITY SCORE 1..100 | 75 | 36 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for AMGN (79) in the Biotechnology industry, and is somewhat better than the same rating for MRK (88) in the Pharmaceuticals Major industry. This means that GILD's stock grew somewhat faster than AMGN’s and somewhat faster than MRK’s over the last 12 months.
AMGN's Profit vs Risk Rating (6) in the Biotechnology industry is in the same range as GILD (10) in the Biotechnology industry, and is in the same range as MRK (28) in the Pharmaceuticals Major industry. This means that AMGN's stock grew similarly to GILD’s and similarly to MRK’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is somewhat better than the same rating for MRK (79) in the Pharmaceuticals Major industry, and is significantly better than the same rating for GILD (96) in the Biotechnology industry. This means that AMGN's stock grew somewhat faster than MRK’s and significantly faster than GILD’s over the last 12 months.
AMGN's Price Growth Rating (7) in the Biotechnology industry is in the same range as MRK (9) in the Pharmaceuticals Major industry, and is in the same range as GILD (17) in the Biotechnology industry. This means that AMGN's stock grew similarly to MRK’s and similarly to GILD’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is in the same range as AMGN (28) in the Biotechnology industry, and is significantly better than the same rating for GILD (100) in the Biotechnology industry. This means that MRK's stock grew similarly to AMGN’s and significantly faster than GILD’s over the last 12 months.
| AMGN | GILD | MRK | |
|---|---|---|---|
| RSI ODDS (%) | 4 days ago 70% | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 53% | 2 days ago 48% | 2 days ago 63% |
| Momentum ODDS (%) | 2 days ago 56% | 2 days ago 62% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 57% | 2 days ago 69% | 2 days ago 55% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 63% | 2 days ago 57% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 65% | 2 days ago 57% |
| Advances ODDS (%) | 8 days ago 61% | 8 days ago 64% | 2 days ago 57% |
| Declines ODDS (%) | 4 days ago 47% | 4 days ago 47% | 10 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 49% | 2 days ago 54% | 2 days ago 69% |
| Aroon ODDS (%) | 2 days ago 56% | 2 days ago 50% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while GILD’s FA Score has 3 green FA rating(s), and MRK’s FA Score reflects 3 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- GILD’s FA Score: 3 green, 2 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 7 TA indicator(s) are bullish while GILD’s TA Score has 4 bullish TA indicator(s), and MRK’s TA Score reflects 6 bullish TA indicator(s).
- AMGN’s TA Score: 7 bullish, 3 bearish.
- GILD’s TA Score: 4 bullish, 3 bearish.
- MRK’s TA Score: 6 bullish, 2 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +2.87% price change this week, while GILD (@Pharmaceuticals: Major) price change was +0.02% , and MRK (@Pharmaceuticals: Major) price fluctuated +1.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.31%. For the same industry, the average monthly price growth was -5.56%, and the average quarterly price growth was +4.88%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
GILD is expected to report earnings on Oct 29, 2026.
MRK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.31% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with JNJ. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then JNJ could also see price increases.